Engineered immune cells take on rare sarcoma in early trial
NCT ID NCT07174427
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized cell therapy called TBI-1301 for people with a rare soft-tissue cancer called synovial sarcoma that has spread or come back. The therapy uses a patient's own immune cells, modified to attack cancer cells with a specific marker (NY-ESO-1). About 5 adults will receive the treatment after chemotherapy to prepare their bodies, and researchers will check if tumors shrink.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYNOVIAL SARCOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kyusyu University Hospital
RECRUITINGFukuoka, Japan
-
Osaka International Cancer Institute
RECRUITINGOsaka, Osaka, 541-8567, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental combo aims to tackle Treatment-Resistant cancers
- New cell therapy targets Hard-to-Treat cancers in first human trial
- Promising combo targets Hard-to-Treat childhood cancers
- New drug trial aims to slow rare Cancer's spread
- Proton beam boost: new hope for inoperable sarcomas?
- New cancer drug AOH1996 enters first human tests